Zheng Quan Shi Bao Wang·2025-12-05 11:24Core Viewpoint - Shanghai Pharmaceuticals has terminated its cooperation agreement with Guizhou Shengnuo Biotechnology regarding the new acid suppressant project X842, and has received a refund of 110 million yuan for the initial payment and development milestone fees [1][2]. Group 1: Termination of Cooperation - The termination agreement was signed on November 18, 2025, and the original cooperation agreement will automatically terminate after the refund is received [1]. - The company stated that this termination will not have a significant impact on its financial status or operating results [2]. Group 2: New Product Approval - On the same day, the company announced that its subsidiary, Jiangsu Dongying Pharmaceutical, received a drug registration certificate for Minoxidil lotion from the National Medical Products Administration [2]. - Minoxidil lotion is used for treating male pattern baldness and alopecia, with a market size of 2.361 billion yuan in China for 2024 [3]. - The approval is expected to enhance the market share and competitiveness of the product, while also providing valuable experience for future generic drug applications [3].